Videos

The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.

Neurology News Network for the week ending January 16, 2021.

The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.

The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.

The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.

The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.

The assistant professor of neurology and anesthesiology at Harvard Medical School detailed the future outlook of ezogabine and whether it may be studied again in patients with ALS.

Episode 5 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Steven Vernino, MD, PhD, of UT Southwestern Medical Center. [WATCH TIME: 4 minutes]

The chief medical officer of Cerevel Therapeutics detailed the TEMPO trials, a trio of studies that will examine tavapadon in patients with early and late-stage Parkinson disease.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.

Neurology News Network for the week ending January 9, 2021.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The director of the Montefiore Headache Center discussed how different treatments work for different patients with migraine.

The chief medical officer of CND Life Sciences and medical director of Honor Health Neurology spoke to the role synuclein has played in advancing PD diagnosis.

The executive director of the Norman Fixel Institute for Neurological Diseases explained how disease-based registries play a crucial part in changing the approval system for neurologic devices in rare diseases.

The assistant professor of neurology and anesthesiology at Harvard Medical School provided context on the potential of motor neuron excitability in patients with ALS.

The director of the Healey & AMG Center for ALS spoke to the recent topline results of a phase 3 study of NurOwn in patients with the neuromuscular disease.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.